Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement
- PDF / 1,066,905 Bytes
- 20 Pages / 595 x 842 pts (A4) Page_size
- 21 Downloads / 220 Views
Wien Klin Wochenschr https://doi.org/10.1007/s00508-020-01781-z
Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement Diana Bonderman · Gerhard Pölzl · Klemens Ablasser · Hermine Agis · Stefan Aschauer · Michaela AuerGrumbach · Christina Binder · Jakob Dörler · Franz Duca · Christian Ebner · Marcus Hacker · Renate Kain · Andreas Kammerlander · Matthias Koschutnik · Alexander Stephan Kroiss · Agnes Mayr · Christian Nitsche · Peter P. Rainer · Susanne Reiter-Malmqvist · Matthias Schneider · Roland Schwarz · Nicolas Verheyen · Thomas Weber · Marc Michael Zaruba · Roza Badr Eslam · Martin Hülsmann · Julia Mascherbauer Received: 19 October 2020 / Accepted: 16 November 2020 © The Author(s) 2020
Summary The prevalence and significance of cardiac amyloidosis have been considerably underestimated in the past; however, the number of patients diagnosed with cardiac amyloidosis has increased significantly recently due to growing awareness of the disease, improved diagnostic capabilities and demographic trends. Specific therapies that improve patient prognosis have become available for certain types of cardiac amyloidosis. Thus, the earliest possible referral of patients with suspicion of cardiac amyloidosis to an experienced center is crucial to ensure rapid diagnosis, early initiation of treatment, and structured pa-
tient care. This requires intensive collaboration across several disciplines, and between resident physicians and specialized centers. The aim of this consensus statement is to provide guidance for the rapid and efficient diagnosis and treatment of light-chain amyloidosis and transthyretin amyloidosis, which are the most common forms of cardiac amyloidosis.
D. Bonderman and G. Pölzl contributed equally to this paper.
M. Hacker Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Department of Radiology and Nuclear Medicine, Medical University of Vienna, Vienna, Austria
D. Bonderman () · S. Aschauer · C. Binder · F. Duca · A. Kammerlander · M. Koschutnik · C. Nitsche · M. Schneider · R. Badr Eslam · M. Hülsmann · J. Mascherbauer Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria [email protected] G. Pölzl · J. Dörler · M. M. Zaruba Department of Medicine III (Cardiology and Angiology), Medical University of Innsbruck, Innsbruck, Austria K. Ablasser · P. P. Rainer · N. Verheyen Division of Cardiology, Medical University of Graz, Graz, Austria H. Agis Department of Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria M. Auer-Grumbach Department of Orthopedics and Trauma Surgery, Medical University of Vienna, Vienna, Austria C. Ebner Internal Department II of Cardiology, Angiology and Internal Intensive Medicine, Elisabethinen Hospital, Linz, Austria
K
Keywords Cardiomyopathy · Heart failure · 99mTcDPD scan · Cardiac MRI · Biopsy
R. Kain Department of Pathology, Medical University of Vienna, Vienna, Austria A. S. Kroiss Dep
Data Loading...
